A thermostable Vibrio cholerae phage and its application
By screening and isolating the high-temperature-resistant Vibrio cholerae phage RDP-VC23062, the problem of the decline in the titer of existing phages at high temperatures is solved, and its long-term preservation and efficient application in aquaculture is achieved, and a new type of biological Prevention and treatment methods.
Patent Information
- Application Number
- CN202410168774.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-02-01
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-02-01
AI Technical Summary
The existing phages have insufficient high temperature resistance during preservation, and their titers have declined in a short period of time, making them difficult to maintain for a long time, affecting their application in aquaculture.
The high-temperature-resistant Vibrio cholerae phage RDP-VC23062 was screened and isolated. The phage has excellent high-temperature resistance and genetic stability. It can maintain its titer in an 85°C water bath and stored for a long time after powder making.
The phage is stable under high temperature conditions and is suitable for reducing the number of Vibrio in water. It provides a new biological control method and replaces antibiotics to prevent and control bacterial diseases in aquaculture animals, which has great potential.
Smart Images

Figure CN118028249B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of microorganisms, and in particular relates to a thermostable Vibrio cholerae phage and application thereof. Background Art
[0002] Vibrio is a class of halophilic, facultative heterotrophic Gram-negative marine bacteria, which is widely distributed in estuaries and coastal ecosystems. It is an important pathogen in aquatic animals (including farmed animals). Its pathogenicity is greatly affected by comprehensive factors such as the physiological state of the host and water quality and environmental conditions. At the same time, it spreads quickly and has a short course of disease, causing great harm to the aquaculture industry. In Asia, vibriosis caused by Vibrio is one of the most common diseases in aquaculture that causes mass deaths of shrimp, fish and shellfish.
[0003] Vibrio cholerae is a Gram-negative bacterium with a short, comma-shaped body, a single flagellum, pili, and some capsules. It is divided into 139 serogroups, of which O1 and O139 can cause cholera. It is widely present in the environment, with a large distribution in seawater, brackish water and freshwater. It is one of the main Vibrio that causes "cholera" and disease in aquatic products. Vibrio cholerae is very easy to survive and has very low requirements for nutritional conditions, but it is extremely difficult to grow in an acidic environment and generally has good alkali tolerance.
[0004] Vibrio cholerae exists in aquatic organisms such as fish, shrimp, crabs and shellfish. It infects hosts and spreads pathogens quickly, which makes prevention and treatment in the breeding process extremely difficult. It has been reported that Vibrio cholerae causes white feces syndrome in white shrimp, causing serious damage to the breeding of white shrimp.
[0005] Bacteriophages are viruses that specifically infect bacteria and replicate inside bacterial cells. They are the most abundant and common organisms on Earth, playing an important role in microbiology, physiology, evolution, and therapy. In recent years, there have been many successful cases of using bacteriophages to treat chronic bacterial infections in humans and animals. Compared with antibiotics, bacteriophages have higher efficacy and safety. Compared with antibiotics, bacteriophages are highly specific. The advantage of this mechanism of action is that bacteriophages only lyse target strains and do not cause damage to symbiotic intestinal flora. At the same time, bacteriophages have the advantages of self-replication, small doses required for treatment, non-toxicity, short R&D cycle, and low production cost. Phage therapy as an alternative means of eliminating pathogens has a very broad and attractive prospect, which deserves in-depth exploration by researchers.
[0006] The successful isolation and application of a large number of lytic bacteriophages against pathogenic bacteria of aquatic animals indicate that there is great potential in using bacteriophages to replace antibiotics to prevent and control bacterial diseases in aquatic animals.
[0007] According to practice, some phages can withstand short-term high temperatures and powder production, but during storage, after 1-3 months, the potency will drop significantly. To solve this problem, in addition to optimizing the phage protective agent, it is crucial to screen phages that are resistant to high temperatures, have stable potency, and can be stored for a long time. Summary of the invention
[0008] In order to solve the problems existing in the prior art, the purpose of the present invention is to provide a high-temperature resistant Vibrio cholerae phage RDP-VC23062 and its application. The high-temperature resistant Vibrio cholerae phage RDP-VC23062 provided by the present invention has excellent high-temperature resistance and strong genetic stability, can be stored for a long time after powdering, and has a high potency, can effectively reduce the number of Vibrio in the water body, protect the growth potential of shrimps, and can provide a new type of biological control method for aquaculture, and has great potential in replacing antibiotics to prevent and control bacterial diseases in aquaculture animals.
[0009] The technical solution of the present invention is:
[0010] The present invention provides a thermostable Vibrio cholerae phage, which is RDP-VC23062, isolated from an aquaculture farm in Haiyang City, Yantai City, Shandong Province, and deposited in the China General Microbiological Culture Collection Center on August 23, 2023. The deposit address is No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC No. 45671. The taxonomic name is Vibrio cholerae bacteriophage.
[0011] Furthermore, the thermostable Vibrio cholerae phage RDP-VC23062 was observed under an electron microscope to have a polyhedral three-dimensional symmetrical head, which encapsulates nucleic acid and has a diameter of about 70 nm, a tail of about 10 nm in length, and a neck connecting the head and the tail, belonging to the Brachyura family of the Caudata order. According to the classification standards of the International Committee on Taxonomy of Viruses (ICTV), the phage RDP-VC23062 is classified as the Brachyura family of the Caudata order.
[0012] Furthermore, the thermostable Vibrio cholerae phage RDP-VC23062 has a nucleotide sequence shown in SEQ ID No.1.
[0013] The titer of the thermostable Vibrio cholerae phage RDP-VC23062 can reach 10 11PFU / mL, the suitable growth temperature is 30-37°C, and the optimal growth temperature is 30°C; and it has been verified by experiments that the phage has excellent high temperature resistance. The phage RDP-VC23062 of the present invention is placed in an 85°C water bath for 45 minutes, and the titer can still be maintained at 10 9 pfu·mL -1 .
[0014] At the same time, at pH = 7, the Vibrio cholerae phage RDP-VC23062 of the present invention has the highest titer, and the titer can be maintained at 10 at pH 5-9. 8 ~10 10 PFU / mL higher level.
[0015] Furthermore, the optimal infection multiplicity of the Vibrio cholerae phage RDP-VC23062 provided by the present invention is 0.01, corresponding to a maximum titer of 10 11 PFU / mL, and the titer remained stable during the subculture process, indicating that the phage has good biological genetic stability and is an excellent choice for the production process.
[0016] The invention provides application of a thermostable Vibrio cholerae phage RDP-VC23062 in preparing medicine for preventing or treating diseases infected by Vibrio cholerae.
[0017] The invention provides application of a thermostable Vibrio cholerae phage RDP-VC23062 in preparing an environmental disinfectant for preventing or treating diseases infected by Vibrio cholerae.
[0018] Furthermore, the present invention also provides a phage composition for preventing or treating Vibrio cholerae infection, comprising the above-mentioned thermostable Vibrio cholerae phage RDP-VC23062.
[0019] Furthermore, the present invention also provides a phage pharmaceutical preparation, comprising the above-mentioned thermostable Vibrio cholerae phage RDP-VC23062 or the above-mentioned phage composition for preventing or treating Vibrio cholerae infection.
[0020] Furthermore, the concentration of the thermostable Vibrio cholerae phage RDP-VC23062 in the phage pharmaceutical preparation is greater than 10 9 PFU / g.
[0021] Furthermore, the bacteriophage drug preparation also includes pharmaceutically acceptable excipients, and its dosage form is powder, granule, lyophilized agent, solution, emulsion, suspension or gel.
[0022] Furthermore, after the thermostable Vibrio cholerae phage RDP-VC23062 liquid of the present invention is sprayed with powder by a spray dryer to prepare a phage powder, the potency can still be maintained at 10 10 pfu·g -1 After the phage powder was stored at 30℃ and 50℃ for 2 months, the phage titer could still be maintained at 10 8 pfu·g -1 , indicating that the phage has good high temperature resistance.
[0023] Compared with the prior art, the thermostable Vibrio cholerae phage RDP-VC23062 provided by the present invention has the following advantages:
[0024] (1) The present invention discovered and isolated a thermostable Vibrio cholerae phage RDP-VC23062 in an aquaculture farm in Haiyang City, Yantai City, Shandong Province. Compared with antibiotics, it has higher effectiveness, safety and high specificity, and has great potential in replacing antibiotics to prevent and control bacterial diseases in aquaculture animals;
[0025] (2) The thermostable Vibrio cholerae phage RDP-VC23062 provided by the present invention can still maintain a high level of titer after being passaged 30 times, indicating that this phage has strong genetic stability, and high stability is of great significance for production and transportation;
[0026] (3) The thermostable Vibrio cholerae phage RDP-VC23062 provided by the present invention has excellent thermostable properties and can withstand short-term high temperatures. After being placed in an 85°C water bath for 45 minutes, the titer can still be maintained at 10 9 pfu·mL -1 It can be stored for a long time after powdering and can maintain stable potency. It has the potential to reduce the number of Vibrio in water and protect the growth of shrimp, and can provide a new type of biological control method for aquaculture.
[0027] Description of biological deposit:
[0028] A thermostable Vibrio cholerae phage RDP-VC23062 was deposited in the China General Microbiological Culture Collection on August 23, 2023. The deposit address is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The deposit number is CGMCC No. 45671, and the taxonomic name is Vibrio cholerae bacteriophage. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 The Vibrio cholerae isolated in Example 1 of the present invention;
[0030] Figure 2 This is a photo of the plaque of the thermophilic Vibrio cholerae phage RDP-VC23062;
[0031] Figure 3 This is an electron micrograph of the thermostable Vibrio cholerae phage RDP-VC23062;
[0032] Figure 4 The results of the optimal growth temperature experiment of the thermostable Vibrio cholerae phage RDP-VC23062;
[0033] Figure 5 The results of the pH stability test of the thermostable Vibrio cholerae phage RDP-VC23062 are shown in Figure 2.
[0034] Figure 6 The experimental results of the optimal multiplicity of infection (MOI) of the thermostable Vibrio cholerae phage RDP-VC23062;
[0035] Figure 7 The results of the stability genetic experiment of the thermostable Vibrio cholerae phage RDP-VC23062;
[0036] Figure 8 The results of the high temperature resistance experiment of the high temperature resistant Vibrio cholerae phage RDP-VC23062;
[0037] Fig. 9 This is a phage powder spraying experiment of the thermostable Vibrio cholerae phage RDP-VC23062;
[0038] Fig.10 These are the results of a high-temperature long-term storage experiment on phage powder prepared from the thermostable Vibrio cholerae phage RDP-VC23062. DETAILED DESCRIPTION
[0039] The present invention is further illustrated below through the description of specific implementation methods, but this is not a limitation of the present invention. Those skilled in the art can make various modifications or improvements based on the basic idea of the present invention, but as long as they do not deviate from the basic idea of the present invention, they are all within the protection scope of the present invention.
[0040] In the following examples, the reagents not specially described are conventional reagents and can be purchased from conventional reagent production and sales companies. The methods used are all prior art unless otherwise specified.
[0041] Example 1 Phage Screening and Identification
[0042] 1. Isolation and identification of Vibrio cholerae:
[0043] (1) Sampling of medium shrimp from an aquaculture farm in Yantai City, Shandong Province was performed. The samples were streaked onto CHROMagar Vibrio chromogenic medium and incubated in a 37°C constant temperature incubator for 18 to 24 hours. The colony morphology and color on the plate were observed and blue colonies were picked.
[0044] (2) Inoculate the cells by streaking onto CHROMagar Vibrio chromogenic medium and subculture and purify for 3 to 5 times until uniform colonies are obtained (e.g. Figure 1 As shown), a single colony was picked and streaked into LB agar medium, and the colony was picked, and then identified by 16SrRNA gene sequencing technology and Vibrio cholerae-specific primer PCR; after the identification was completed, the bacterial moss was scraped to prepare a bacterial liquid, and then 500 μL of the bacterial liquid was mixed with 500 μL of 30% glycerol broth to obtain Vibrio cholerae bacterial liquid, which was stored in a -80°C refrigerator.
[0045] 2. Isolation and purification of bacteriophages:
[0046] (1) Seawater treatment: Collect aquaculture seawater from an aquaculture farm, filter it with filter paper, then centrifuge the filtered leaching solution at 10,000 rpm for 5 min, take the supernatant and filter it with a 0.22 μm filter, and store the seawater filtrate at 4°C for later use;
[0047] (2) Phage enrichment: 0.1 mL of Vibrio cholerae culture and 1 mL of seawater filtrate were added to 5 mL of LB broth and cultured overnight at 37°C in a shaking incubator. The culture was then centrifuged at 10,000 rpm for 10 min. The supernatant was filtered through a 0.22 μm filter and the filtrate was used for later use.
[0048] (3) Phage isolation: The double plate method was used to isolate phages. 0.1 mL of the host Vibrio cholerae bacterial liquid was mixed with 0.6% LB soft agar and spread on an LB solid plate. After the soft agar solidified, 0.1 mL of the seawater filtrate was spotted on the plate and allowed to stand until the mixed liquid was absorbed. After incubation at 37°C for 6 to 8 h, transparent plaques were picked up with an inoculation loop and placed in 2 mL of SM buffer. The plate was stored at 4°C overnight to allow the phages to be completely released, thereby obtaining phage liquid.
[0049] (4) Phage purification: The double plate method is used to purify phages. Take 0.1 mL of phage liquid and 0.2 mL of host Vibrio cholerae liquid, mix them evenly, add soft agar cooled to about 50°C and mix them evenly, then spread on two plates, place in a 37°C incubator for incubation for 6 to 8 hours, pick out a single transparent spot with smooth edges and put it in 1 mL of SM buffer, and store it at 4°C overnight. Take 0.1 mL of the overnight stored extract and 0.1 mL of Vibrio cholerae liquid, mix them, add soft agar cooled to about 50°C and mix them evenly, spread on two plates, and incubate in a 37°C incubator for 4 to 6 hours. Follow these steps to purify until the plaques are uniform in size and have smooth edges. Purified phages are obtained. Figure 2 shown.
[0050] (5) Preparation of phage: 0.2 mL of host Vibrio cholerae liquid and 1 mL of purified phage liquid were added to 50 mL of LB broth, cultured overnight at 37°C in a shaking incubator, and then centrifuged at 10,000 rpm for 10 min. The supernatant was filtered through a 0.22 μm filter to obtain the phage filtrate for use;
[0051] (6) Preservation of bacteriophages: Add Vibrio cholerae and bacteriophage suspension to 60% glycerol in a ratio of 1:1 and store at -80°C.
[0052] Specifically, the thermostable Vibrio cholerae phage RDP-VC23062 was deposited in the China General Microbiological Culture Collection Center on August 23, 2023. The deposit address is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The deposit number is CGMCC No. 45671, and the taxonomic name is Vibrio cholerae bacteriophage.
[0053] 3. Electron microscopic observation of bacteriophage
[0054] Take 20 μL of liquid containing crude phage particles and drop it on the copper mesh. Let it precipitate naturally for 15 minutes, and use filter paper to absorb excess liquid from the side. Add a drop of 2% phosphotungstic acid (PTA) on the copper mesh to stain the phage for 10 minutes, then use filter paper to absorb the staining liquid from the side. After the sample is dry, use an electron microscope to observe the phage morphology, such as Figure 3 shown.
[0055] From the electron microscope image, we can see that the phage RDP-VC23062 has a polyhedral, three-dimensionally symmetrical head that wraps around nucleic acid, with a diameter of 70nm, a tail about 10nm long, and a neck connecting the head and tail. According to the classification standards of the International Committee on Taxonomy of Viruses (ICTV), the phage RDP-VC23062 is classified as the Brachyura family of the Caudata order.
[0056] 4. Phage whole genome sequencing and analysis:
[0057] The library was constructed using the Illumina TruSeqTMNano DNA Sample Prep Kit method; the specific steps are as follows:
[0058] ① The library was constructed with 1 μg of phage genomic DNA as the starting amount;
[0059] ②Covaris M220 ultrasonically breaks DNA into 300-500 bp;
[0060] ③ Fill in the 3' end and add A, connect the index adapter (TruSeqTMNano DNA Sample Prep Kit);
[0061] ④Library enrichment, PCR amplification for 8 cycles;
[0062] ⑤2% agarose gel to recover the target band (Certified Low Range Ultra Agarose);
[0063] ⑥TBS380 (Picogreen) quantification, mixed according to the data ratio and loaded on the machine;
[0064] ⑦ Bridge PCR amplification was performed on the cBot solid phase carrier to generate clusters;
[0065] ⑧Illumina Hiseq sequencing platform, performing 2×150bp sequencing.
[0066] The sequencing result is shown in SEQ ID NO:1.
[0067] Example 2 Study on the biological characteristics of bacteriophage
[0068] 1. Determination of phage titer
[0069] The phage RDP-VC23062 and 100 μL of host bacteria cultured to the exponential phase were mixed into a 5 mL centrifuge tube and shaken up and down and placed on LB semi-solid agar, completely covering the 20 mL LB solid agar plate (9 cm diameter). After the semi-solid was dried, 100 μL of the purified phage concentrate was taken and placed on the plate. Repeat 3 times, cultured at 37 ° C overnight, deducted the plaques in 20 mL SM buffer, and placed at 4 ° C. The next day, the supernatant was taken, filtered through a 0.22 μm filter membrane, and 100 μL of the filtrate was diluted 10 times with sterile water. Then, 100 μL of the bacterial solution and phage solution were mixed on double plates, and the plates were cultured in a 37 ° C incubator overnight. Select a countable plate, count the phage plaques, and calculate the phage titer (pfu / mL) as the number of plaques × dilution factor / sample volume (mL).
[0070] Experimental results and analysis:
[0071] The titer of bacteriophage RDP-VC23062 can reach 10 11 PFU / mL.
[0072] 2. Determination of the optimal growth temperature of bacteriophage
[0073] The phage stock solution was gradiented tenfold to a concentration of 10 6 PFU / ml, take 100 μL and mix with an equal volume of 108 PFU / ml of Vibrio cholerae bacterial liquid were mixed, poured into double-layer plates, and cultured at 15℃, 20℃, 25℃, 30℃, 37℃, 40℃, 45℃, and 50℃ for 6 to 8 hours, and the titer of the phage was detected.
[0074] Experimental results and analysis:
[0075] The results of the determination of the optimal growth temperature of bacteriophage are as follows Figure 4 As shown, the suitable growth temperature of the phage is between 30 and 37°C, and the optimal growth temperature is 30°C.
[0076] 3. Determination of pH stability of bacteriophage
[0077] The pH value of LB liquid medium was adjusted to 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12, respectively, and 100 μL of each was mixed with an equal volume of 10 11 The phage stock solutions of 100 PFU / ml were mixed and placed at 37°C for 2 hours. The titer was determined by the double-layer plate method, and 3 replicates were set for each pH. The pH stability curve of phage RDP-VC-23062 was drawn with pH as the horizontal axis and the logarithm of phage titer as the vertical axis.
[0078] Experimental results and analysis:
[0079] The results are as follows Figure 5 As shown in Figure 2, the titer of bacteriophage RDP-VC23062 was the highest at pH 7, and its titer could be maintained at 10 at pH 5-9. 8 ~10 11 PFU / mL higher level.
[0080] 4. Determination of the optimal phage infection multiplicity (MOI)
[0081] Experimental methods:
[0082] MOI refers to the ratio of the number of phages to the number of host bacteria at the initial infection. The concentration of the host bacteria cultured to the exponential phase was adjusted to 10 8 CFU / mL. Set the MOI to 0.0001, 0.001, 0.01, 0.1, 1, 10, and 100, respectively. Add the titered phage solution to the bacterial solution in proportion, 500 μL of bacterial solution and phage solution respectively, mix well, and culture at 30°C, 200 r / min for 5 hours. Centrifuge the mixed culture at 10000 r / min for 10 minutes, and measure the phage titer. The multiplicity of infection with the highest titer is the optimal multiplicity of infection. The optimal multiplicity of infection of bacteriophage RDP-VC23062 was determined by the above method.
[0083] Experimental results and analysis:
[0084] The results are as follows Figure 6 As shown in the figure, the phage titer of phage RDP-VC23062 is the highest when the infection multiplicity is 0.01, so the optimal infection multiplicity of phage RDP-VC-23062 is 0.01, corresponding to the highest titer of 10 11 PFU / mL.
[0085] 5. Phage Stability Genetic Experiment
[0086] The phage was subcultured 30 times, with equal amounts of phage and host bacteria added to the culture medium for each generation. Each generation was cultured for 6 hours, and then double plates were spread. After the phage was subcultured for 29 generations, its titer was determined. Figure 7 shown.
[0087] Depend on Figure 7 It can be seen that the titer of the phage remains stable during the process of propagation, indicating that the phage has good biological genetic stability and is an excellent choice for the production process.
[0088] 6. Experiment on high temperature resistance of bacteriophage
[0089] The prepared phage stock solution was placed in a water bath at 85°C for 45 minutes, and then the treated solution was centrifuged and filtered, graded diluted, and its titer was measured.
[0090] The results of the phage thermostability test are as follows Figure 8 As shown, the phage was placed in a water bath at 85°C for 45 minutes, and the titer was still maintained at 10 9 pfu·mL -1 .
[0091] Example 3 Application performance test of bacteriophage
[0092] 1. Phage dusting experiment
[0093] The prepared phage stock solution and auxiliary materials (starch, β-cyclodextrin, mannitol) were mixed in the ratio of stock solution, starch, β-cyclodextrin, mannitol = 100:5:8:3 (v / m), placed in a spray dryer, set the inlet temperature to 80°C, and the outlet temperature to 58°C, collected the phage powder, and determined its potency.
[0094] The results of the bacteriophage powder titer test are as follows Fig. 9 As shown in the figure, the phage liquid was sprayed with powder by a spray dryer to make phage powder, and the potency can still be maintained at 10 10 pfu·g -1 .
[0095] 2. Experiment on long-term storage of bacteriophage powder at medium and high temperature
[0096] The prepared Vibrio cholerae RDP-VC23062 phage powder was stored in two medium and high temperature environments of 30°C and 50°C, and samples were taken at time periods of 1 day, 10 days, 20 days, 30 days, 40 days, 50 days, and 60 days to determine the phage titer.
[0097] The results of the phage powder titer test are as follows Fig.10 As shown in the figure, the phage powder was stored at 30℃ and 50℃ for 2 months, and the phage titer could still be maintained at 10 8 pfu·g -1 , the phage has good high temperature resistance.
[0098] 3. Feed Addition Experiment
[0099] In the process of shrimp farming, a feed mixer is needed to stir the feed, and heating is required in this process. The potency of general bacteriophages will be reduced when put into the feed. The high temperature resistant cholera phage powder is added to the feed and used as a feed additive to reduce the number of Vibrio in the water and protect the health of aquatic animals.
[0100] The cholera phage RDP-VC23062 powder was selected as a feed additive, and 50L of aquaculture water, 40 healthy white shrimp fry and necessary aquaculture equipment were prepared. The shrimp fry were divided into two groups, and a control group of 20 shrimps in each group was given conventional feed, and the number of Vibrio was recorded regularly; an experimental group was set up: the shrimp fry were divided into two groups, each with 20 shrimps, and the control group was given feed with phage powder added, and the number of Vibrio was recorded regularly. The two groups of shrimp fry were subjected to the same aquaculture management, including water quality management, feed feeding, etc. After 20 days, samples were taken from the water body, the number of Vibrio was detected, and the data was recorded. At the same time, the growth of the two groups of shrimps was observed and recorded, including survival rate, growth rate, etc. The two groups of experimental data were compared to analyze the effect of adding phage powder on reducing the number of Vibrio and protecting the growth of shrimp. The experimental results are shown in Table 1.
[0101] Table 1
[0102]
[0103]
[0104] As shown in Table 1, the experimental results show that the feed with phage powder added can significantly reduce the number of Vibrio in the water, effectively protect the growth of shrimp, increase the survival rate of shrimp, and accelerate the growth rate. This experiment shows that phage powder as a feed additive has the potential to reduce the number of Vibrio in the water and protect the growth of shrimp, and can provide a new biological control method for aquaculture.
[0105] The above embodiments are merely illustrative of the principles and effects of the present invention, and are not intended to limit the present invention. Anyone familiar with the art may modify or alter the above embodiments without departing from the spirit and scope of the present invention. Therefore, all equivalent modifications or alterations made by a person of ordinary skill in the art without departing from the spirit and technical concept disclosed by the present invention shall still be covered by the claims of the present invention.
Claims
1. A thermostable Vibrio cholerae phage, characterized in that: The bacteriophage is Vibrio cholerae phage RDP-VC23062, which is deposited in the China General Microbiological Culture Collection Center with a deposit number of CGMCC No.45671.
2. Use of the thermostable Vibrio cholerae phage RDP-VC23062 according to claim 1 in the preparation of a medicament for preventing or treating diseases infected by Vibrio cholerae.
3. Use of the thermostable Vibrio cholerae phage RDP-VC23062 according to claim 1 in the preparation of an environmental disinfectant for preventing or treating diseases infected by Vibrio cholerae.
4. A bacteriophage composition for preventing or treating Vibrio cholerae infection, characterized in that: It comprises the thermostable Vibrio cholerae phage RDP-VC23062 described in claim 1.
5. A bacteriophage pharmaceutical preparation, characterized in that: It comprises the thermostable Vibrio cholerae phage RDP-VC23062 as described in claim 1 or the phage composition as described in claim 4.
6. The bacteriophage pharmaceutical preparation according to claim 5, characterized in that The concentration of the thermostable Vibrio cholerae phage RDP-VC23062 is greater than 10 9 PFU / g.
7. The bacteriophage pharmaceutical preparation according to claim 5, characterized in that: The bacteriophage drug preparation also includes pharmaceutically acceptable excipients, and its dosage form is powder, granule, lyophilized agent, solution, emulsion, suspension or gel.
